A Randomized, Open-Label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-Containing Therapy With a Cross-Over Period for Progressing Patients.

Trial Profile

A Randomized, Open-Label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-Containing Therapy With a Cross-Over Period for Progressing Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2014

At a glance

  • Drugs Afatinib (Primary) ; Cetuximab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2013 Results for after crossover presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jul 2012 Actual end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top